The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers

Brigatinib (AP26113) is a dimethylphosphine oxide group-containing tyrosine kinase inhibitor (TKI) constructed around a bisanilinopyrimidine scaffold with potent activity against the anaplastic lymphoma kinase (ALK) and several other targets. Despite the activity of first- and second-generation ALK...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Onco Targets Ther
Главные авторы: Sabari, Joshua K, Santini, Fernando C, Schram, Alison M, Bergagnini, Isabella, Chen, Ruqin, Mrad, Chebli, Lai, W Victoria, Arbour, Kathryn C, Drilon, Alexander
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2017
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388194/
https://ncbi.nlm.nih.gov/pubmed/28435288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S109295
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы